Your fact-checks will appear here
Commune in Haute-Corse, France
A comprehensive review of the available reporting shows no completed randomized, placebo‑controlled trials that prove ivermectin or mebendazole are effective cancer therapies; the literature instead c...
Two registered early‑phase clinical trials combine ivermectin with immune checkpoint inhibitors for cancer: a phase I/II investigator‑initiated trial testing oral ivermectin with balstilimab (and an e...
Approved human doses of oral ivermectin for parasitic diseases are weight‑based and generally center on about 200 micrograms/kg as a single dose (e.g., 200 mcg/kg) for strongyloidiasis and onchocercia...
Available evidence shows that gastrointestinal (GI) side effects — nausea, vomiting, diarrhea, abdominal pain — are known and relatively common adverse reactions to ivermectin in general use, but rigo...
Clinical testing of ivermectin as a cancer therapy is very limited and largely early-phase: the clearest ongoing human study is a phase I/II trial combining ivermectin with the PD‑1 agent balstilimab ...
Only a single actively registered randomized or early-phase trial of ivermectin in human cancer patients is clearly documented in the available reporting: a phase I/II study combining oral ivermectin ...
Clinical investigation of ivermectin in human cancer patients is extremely limited: the only clearly documented clinical trial testing ivermectin in cancer patients is a phase I/II study for metastati...
Laboratory and animal studies show ivermectin can slow cancer cell growth, trigger cancer-cell death pathways, and boost anti-tumor immunity in models — and small clinical testing has begun — but ther...
A small, unpublished-at-the-time prospective study presented at the 2025 ASCO meeting found 41–39% of long‑distance runners aged ~35–50 had at least one colorectal polyp and about 15% had advanced ade...
Two U.S.-registered trials testing ivermectin in cancer patients are identifiable in recent reporting: a Phase I/II study combining ivermectin with the PD‑1 agonist balstilimab for metastatic triple‑n...
European investigators have moved ivermectin from petri dishes into a very small number of human studies, but robust evidence of benefit in cancer is lacking: a 2025 ASCO abstract reported a phase I/I...
There is currently no established clinical protocol for routine monitoring specifically when ivermectin is given to cancer patients; human evidence is limited to small early-phase trials and anecdote,...
Clinical testing of ivermectin in human oncology is extremely limited and concentrated in early-phase trials for metastatic triple‑negative breast cancer (mTNBC), notably a phase I/II (sometimes repor...
Clinical oncology trials and reports show oral ivermectin regimens in cancer studies most commonly as intermittent, multi-day courses within 21‑day cycles — for example oral ivermectin on days 1–3, 8–...
Clinical oncology investigations and case reports have used a wide range of ivermectin doses and schedules: from standard antiparasitic doses (150–400 µg/kg) cited in reviews to high, repeat oral regi...
There are very few registered clinical trials testing ivermectin in cancer: the clearest active, publicly listed study is NCT05318469 (a phase I/II trial combining oral ivermectin with anti‑PD‑1 immun...
No completed human studies specifically reporting the safety or pharmacokinetics (PK) of high‑dose ivermectin in cancer patients have been published in the sources provided; the literature instead con...
Clinical testing of ivermectin in cancer patients remains nascent: searches of the clinical literature and trial registries identify essentially one active early-phase trial combining ivermectin with ...
Randomized clinical trials do not support a consistent protective effect of acetyl‑L‑carnitine (ALC) against chemotherapy‑induced peripheral neuropathy (CIPN) across different chemotherapy agents; in ...
PSA doubling time (PSADT) measures how long it takes for prostate‑specific antigen (PSA) in the blood to double and is calculated by modeling PSA’s exponential rise over time; it is used after radical...